Acceleron Pharma (XLRN)

178.75  -0.93 (-0.52%)

After market: 179.92 +1.17 (+0.65%)

News Image
a year ago - InvestorPlace

3 Dow Stocks to Take Seriously in 2023

The top Dow stocks for 2023 are all big free cash flow generators that ought to be able to cope with whatever next year brings.

News Image
2 years ago - InvestorPlace

Merck Is a Dividend Play Ready to Get Back in Gear

Pfizer has been beating MRK stock in 2021, but that relative performance may reverse next year, with new drugs and acquisitions ahead.

News Image
3 years ago - The Motley Fool

Is Merck's Planned Acquisition of Acceleron in Trouble?

There's nothing to worry about with a recent delay.

News Image
3 years ago - Halper Sadeh LLP

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ROG, RRD, XLRN, ADMS; Shareholders are Encouraged to Contact the Firm

/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Rogers Corporation (NYSE: ROG)...

News Image
3 years ago - Zacks Investment Research

Acceleron Pharma (XLRN) Reports Q3 Loss, Lags Revenue Estimates

Acceleron (XLRN) delivered earnings and revenue surprises of 1.04% and -6.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

News Image
3 years ago - Bloomberg

Farallon Capital Opposes Terms of Merck’s Acceleron Takeover

Another top-10 holder in Acceleron Pharma Inc. has come out against its proposed $11.5 billion takeover by Merck & Co. Inc., arguing the sale price undervalues the company.

News Image
3 years ago - WeissLaw LLP

SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

News Image
3 years ago - Zacks Investment Research

Earnings Preview: Acceleron Pharma (XLRN) Q3 Earnings Expected to Decline

Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News Image
3 years ago - Halper Sadeh LLP

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CXP, XLRN, HRC, DSPG; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / October 28, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Columbia Property Trust, Inc. (NYSE:CXP) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to funds managed by Pacific Investment Management Company LLC for $19.30 per share in cash. If you are a Columbia Property

News Image
3 years ago - Zacks Investment Research

Merck (MRK) Beats on Q3 Earnings & Sales, Ups 2021 View

Merck (MRK) beats Q3 estimates for earnings and sales. It raises financial guidance for 2021. The stock moves up in the pre-market trading session.

News Image
3 years ago - WeissLaw LLP

SHAREHOLDER ALERT: WeissLaw LLP Reminds COLB, XLRN, ACBI. and ECHO Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

News Image
3 years ago - Halper Sadeh LLP

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates KRA, ESBK, CXP, KOR, XLRN; Shareholders are Encouraged to Contact the Firm

/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Kraton Corporation (NYSE: KRA)...

News Image
3 years ago - Zacks Investment Research

Merck (MRK) to Report Q3 Earnings: What's in the Cards?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.

News Image
3 years ago - Halper Sadeh LLP

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates AZPN, HRC, KOR, XLRN; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / October 23, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Aspen Technology, Inc. (NASDAQ:AZPN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with certain of Emerson Electric Co.'s industrial software businesses. Under the terms of the agreement, Aspen shareholders will

News Image
3 years ago - WeissLaw LLP

SHAREHOLDER ALERT: WeissLaw LLP Reminds MDP, GWB, XLRN and HFC Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

News Image
3 years ago - Halper Sadeh LLP

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UMPQ, XLRN, ADMS, AZPN; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / October 21, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Umpqua Holdings Corporation (NASDAQ:UMPQ) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Columbia Banking System, Inc. Under the terms of the agreement, Umpqua shareholders will receive 0.5958 of a share of Columbia

News Image
3 years ago - Bloomberg

Bristol-Myers Plans to Exit Acceleron Stake With Merck Deal

Bristol-Myers Squibb Co. is planning to tender its shares in Acceleron Pharma Inc. after Merck & Co. agreed to buy the biotechnology company for $11.5 billion, according to people with knowledge of the matter.

News Image
3 years ago - Halper Sadeh LLP

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UMPQ, DSPG, JMP, KOR, XLRN, VNE; Shareholders are Encouraged to Contact the Firm

/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Umpqua Holdings Corporation...

News Image
3 years ago - WeissLaw LLP

Shareholder Alert: WeissLaw LLP Reminds MDP, GWB, XLRN and HFC Shareholders About Its Ongoing Investigations

/PRNewswire/ -- Meredith Corporation (NYSE: MDP) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of...

News Image
3 years ago - Halper Sadeh LLP

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates COLB, AZPN, XLRN; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / October 15, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Columbia Banking System, Inc. (NASDAQ:COLB) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Umpqua Holdings Corporation. Under the terms of the agreement, Umpqua shareholders will receive 0.5958 of a share of

News Image
3 years ago - Halper Sadeh LLP

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XLRN, AZPN, UMPQ, TGP; Shareholders are Encouraged to Contact the Firm

/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Acceleron Pharma Inc. (NASDAQ:...

News Image
3 years ago - Bloomberg

Bristol-Myers Is Said to Have Weighed Offer for Acceleron

Acceleron Pharma Inc. engaged with several companies including Bristol-Myers Squibb Co. to gauge their interest in a potential acquisition before Merck & Co. agreed to buy the company for $11.5 billion in the biggest biotechnology deal of 2021, according to a person familiar with the matter.

News Image
3 years ago - Halper Sadeh LLP

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XLRN, ECHO, KRA, EBMT; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / October 8, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Acceleron Pharma Inc. (NASDAQ:XLRN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Merck & Co., Inc. for $180.00 per share in cash. If you are an Acceleron shareholder, click here to learn more about your rights and

News Image
3 years ago - The Motley Fool

Is an Acquisition of Acceleron a Smart Move for Merck?

Merck will pick up a promising pipeline candidate with the deal.

News Image
3 years ago - WeissLaw LLP

SHAREHOLDER ALERT: WeissLaw LLP Reminds XLRN, JMP, ECHO, and KDMN Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

News Image
3 years ago - Halper Sadeh LLP

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XLRN, GSKY, GWB, VLY, NOTV; Shareholders are Encouraged to Contact the Firm

/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Acceleron Pharma Inc. (NASDAQ:...